Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I
A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I

NCT06926621

Enrolling By InvitationPhase 2

Sponsor: Vertex Pharmaceuticals Incorporated

Conditions: Myotonic Dystrophy Type 1 (DM1)

Interventions: VX-670

Countries: United States, Australia, Belgium, Canada, Germany, Netherlands, Spain, United Kingdom

The purpose of the study is to evaluate the long-term safety and tolerability, efficacy and pharmacokinetics of VX-670 in participants with Myotonic Dystrophy Type I (DM1).

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Key Inclusion Criteria:

• Completed study drug treatment in parent study VX23-670-001 (NCT06185764)

Key Exclusion Criteria:

• History of any illness or any clinical condition as pre-specified in the protocol

Other protocol defined Inclusion/Exclusion criteria may apply.
Locations (15)
  • St Louis, Missouri, United States
  • Richmond, Virginia, United States
  • Auchenflower, Australia
  • Melbourne, Australia
  • Leuven, Belgium
  • Montreal, Canada
  • Montreal, Canada
  • Ottawa, Canada
  • Québec, Canada
  • München, Germany
  • Maastricht, Netherlands
  • Valencia, Spain
  • Glasgow, United Kingdom
  • London, United Kingdom
  • Sheffield, United Kingdom